IonMed’s New Direction Documented in Israel21C

Editor’s note: IonMed was featured in Israel21C on November 16, 2015

Cold-plasma incision sealer to be used in skin grafts

By: Abigail Klein Leichman

One year after receiving CE clearance in Europe for its Bioweld1 cold-plasma system for closing surgical incisions, Israel’s IonMed has completed clinical trials in Queen Astrid Military Hospital in Brussels — the largest burn center in Europe – showing the system’s advantages in skin-graft fixation over sutures, fibrin glue or staples.


Ionmed’s Bioweld1 System

“Staples account for about 90-plus percent of the market. Fibrin glue is very expensive so although it’s good, many hospitals and clinics cannot afford to use it,” explains IonMed clinical manager Dr. Yaara Yarmut. “Staples create local pressure points that can lead to necrosis or infection. The advantage of our device is that it is cheaper than fibrin glue and more efficient than staples.”

The startup, based in the Lower Galilee city of Yokneam Ilit, will next focus on the treatment of skin diseases including acne. Yarmut said cold plasma has characteristics that can change the mechanisms involved in the formation of acne lesions. “We’re working on performing a clinical trial in Europe for this application,” she says.

IonMed CEO Shai Levanon says cold plasma “holds enormous promise as a new therapeutic paradigm in wound care, and more broadly in medicine.”

In addition to sealing wounds, cold plasma speeds healing and has antimicrobial properties.

Until now, the company has been supported by its major shareholders, The Trendlines Group and Generali Financial Holdings Fund.

“However, to make progress in commercialization, especially after our success in the skin-graft trial, we are looking for additional investors to join us,” says IonMed CEO Shai Levanon.

Read the full article on Israel21C.

Leave a Reply

  • Welcome to Trendlines

    We invest in, incubate, and support early-stage, high-promise medical and agricultural technology companies in Israel, a global leader in start-up ingenuity. Read More >

  • Categories

  • Subscribe to Our Newsletter

  • Stay in Touch

    icon-facebook Like us on Facebook

    icon-Twitter Follow us on Twitter

    icon-Linkedin Connect with us on Linkedin

    YouTube-color See us on YouTube

    flipboard  Read us on Flipboard

    google+_icon Join us on Google+

Font Resize